Dopa-testotoxicosis: disruptive hypersexuality in hypogonadal men with prolactinomas treated with dopamine agonists

[1]  A. Kaptein,et al.  Quality of life (QoL) impairments in patients with a pituitary adenoma: a systematic review of QoL studies , 2015, Pituitary.

[2]  T. J. Moore,et al.  Reports of pathological gambling, hypersexuality, and compulsive shopping associated with dopamine receptor agonist drugs. , 2014, JAMA internal medicine.

[3]  M. Silber,et al.  Impulse control disorders in patients with dopamine agonist‐treated prolactinomas and nonfunctioning pituitary adenomas: a case–control study , 2014, Clinical endocrinology.

[4]  L. Stoeckel,et al.  Investigation of impulsivity in patients on dopamine agonist therapy for hyperprolactinemia: a pilot study , 2014, Pituitary.

[5]  G. Stalla,et al.  Polymorphisms of the drug transporter gene ABCB1 predict side effects of treatment with cabergoline in patients with PRL adenomas. , 2012, European journal of endocrinology.

[6]  P. Valkovič,et al.  Impulse Control Disorders Associated With Dopaminergic Medication in Patients With Pituitary Adenomas , 2011, Clinical neuropharmacology.

[7]  Alberto Fernández,et al.  Prevalence of pituitary adenomas: a community‐based, cross‐sectional study in Banbury (Oxfordshire, UK) , 2010, Clinical endocrinology.

[8]  W. Ludlam.  Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK) , 2010 .

[9]  H. Falhammar,et al.  Pathological gambling and hypersexuality in cabergoline‐treated prolactinoma , 2009, The Medical journal of Australia.

[10]  D. Vinkers,et al.  A case of mania after long-term use of quinagolide. , 2007, General hospital psychiatry.

[11]  A. Beckers,et al.  High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. , 2006, The Journal of clinical endocrinology and metabolism.

[12]  A. Colao,et al.  Advances in the treatment of prolactinomas. , 2006, Endocrine reviews.

[13]  M. Burns,et al.  Case-Control Study , 2020, Definitions.

[14]  P. Cappabianca,et al.  Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis. , 2004, The Journal of clinical endocrinology and metabolism.

[15]  G. Vitale,et al.  Six months of treatment with cabergoline restores sexual potency in hyperprolactinemic males: an open longitudinal study monitoring nocturnal penile tumescence. , 2004, The Journal of clinical endocrinology and metabolism.

[16]  R. Quinton,et al.  Medical Therapy of Macroprolactinomas in Males: I. Prevalence of Hypopituitarism at Diagnosis. II. Proportion of Cases Exhibiting Recovery of Pituitary Function , 2001, Pituitary.

[17]  D. Pauler,et al.  Primary medical therapy of micro- and macroprolactinomas in men. , 2000, The Journal of clinical endocrinology and metabolism.

[18]  C. Baird,et al.  The pilot study. , 2000, Orthopedic nursing.

[19]  C. Raftopoulos,et al.  Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. , 1999, The Journal of clinical endocrinology and metabolism.

[20]  J. Webster,et al.  A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea , 1994, The New England journal of medicine.

[21]  M. Bergsneider,et al.  Acute psychosis in a woman with a prolactinoma. , 1987, International Journal of Neuroscience.

[22]  R. Firth.  Function , 1955, Yearbook of Anthropology.